Next Article in Journal
Risk of Osteoporosis-Related Fracture in Children and Adolescents with Intellectual Disability
Previous Article in Journal
Analysis of HER2 Expression in Different Histological Subtypes and IHC-Based Molecular Variants of Muscle-Invasive Bladder Carcinoma
Previous Article in Special Issue
Thermography in Stroke—A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 61
Issue 10
10.3390/medicina61101760
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke

by
Silvina Iluţ
1,
Valer Donca
2,*,
Antonia Eugenia Macarie
2,
Ştefan Cristian Vesa
3,
Raluca Maria Pop
3,
Vitalie Văcăraş
4,
Diana Şipoş-Lascu
4,
Ioana Cristina Bârsan
4,
Lăcrămioara Perju-Dumbravă
4,
Ovidiu Sorin Chiroban
5,
Camelia Alexandra Coadă
6 and
Anca Dana Buzoianu
3
1
2nd Department, Faculty of Medical Assistance and Health Sciences, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
2
Department of Geriatrics-Gerontology, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
3
Department of Pharmacology, Toxicology and Clinical Pharmacology, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania
4
Department of Neurosciences, Faculty of Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
5
Department of Forensic Medicine, Faculty of Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
6
Department of Morpho-functional Sciences, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
Medicina 2025, 61(10), 1760; https://doi.org/10.3390/medicina61101760
Submission received: 26 August 2025 / Revised: 18 September 2025 / Accepted: 26 September 2025 / Published: 28 September 2025
(This article belongs to the Special Issue Stroke: Diagnostic Approaches and Therapies: 2nd Edition)
Versions Notes

Abstract

Background and Objectives: The aim of this study was to evaluate the potential predictive value of VKORC1, CYP4F2, and GGCX polymorphisms, as well as other clinical and demographic factors, for 5-year mortality in patients with acute ischemic stroke (AIS). Materials and Methods: The study enrolled 252 patients who were consecutively hospitalized for AIS. Demographic data, comorbidities, and laboratory tests were collected. Genotyping of the VKORC1 rs9923231 (-1639G > A; VKORC1*2), CYP4F2 rs2108622 (1347C > T), and GGCX rs11676382 (12970C > G) polymorphisms was performed. Mortality was noted if it occurred within five years following the 30 days after discharge, using the National Health Insurance House registry. Results: Death was recorded in 71 (28.1%) patients. In multivariate analysis the following variables were independent variables associated with 5-year mortality: age > 72 years (OR 2.83 (95%CI 1.32; 6.08), p = 0.007), a lesion volume > 12.6 mL (OR 4.05 (95%CI 2.05; 7.99), p < 0.001), and an NIHSS score > 7 (OR—2.64 (95%CI 1.31; 5.31), p = 0.006). VKORC1 (-1639G > A) SNP m/m variant was only marginally associated with mortality. Conclusions: In this study which included AIS patients, VKORC1, CYP4F2, and GGCX polymorphisms did not independently predict mortality. The VKORC1 variant was only marginally associated with mortality, but this was attenuated after correction for multiple testing. Advanced age, NIHSS score, and the lesion volume were independent predictors of long-term mortality in AIS patients.

1. Introduction

Acute ischemic stroke (AIS) is one of the leading causes of death in patients with cardiovascular diseases (1 in 6 deaths from cardiovascular disease) [1]. It is also a major source of short- and long-term disability, which comes with a high socio-economic cost [2]. Despite improvements in acute management (intravenous thrombolysis within 4.5 h and endovascular thrombectomy for anterior-circulation large-vessel occlusion within 6 h), the long-term outcome for AIS patients is still relatively poor [1]. Studies showed that these interventions more likely improve the short/medium term outcomes rather than long-term survival [3].
In Romania, AIS is a major public health issue, with an incidence that rose from 87.6 to 201 per 100,000 between 2007 and 2015, which indicates a worse-than-average burden compared to Western Europe [4]. Despite some improvements in stroke care in recent years (an increase in the thrombolysis rate from 0.8% to 5.4% between 2017 and 2022), mortality and long-term disability rates remain among the highest in the European Union. The 5-year mortality rate after an ischemic stroke in Romania is estimated at 21.6%, almost twice the European average [5].
Current research is increasingly focused on identifying genetic and molecular markers that could help more accurately predict the long-term mortality risk in AIS. To date, no studies have investigated the potential predictive role of polymorphisms involved in vitamin K (VK) metabolism for long-term mortality in AIS patients who are not receiving treatment with VK antagonists. Studies on European populations showed that the VKORC1 rs9923231 A-allele is common (minor-allele frequency ~40–45%); in Romanians, an A-allele frequency as high as 42% was reported, comparable to other European cohorts [6,7]. In European-Americans, the VKORC1 haplotype Group A associated with a low dose of warfarin has a prevalence of ~35%, and VKORC1 variants explain a larger share of dose variability than in African-Americans [8]. The CYP4F2 rs2108622 minor allele is frequent in Europeans, European Americans, and Central/Eastern European populations (25–30%; 30%; 23–32%, respectively) [9,10,11]. The GGCX rs11676382 minor allele is much less frequent than VKORC1 or CYP4F2 in Europeans (7–12%) [12]. We previously investigated the implication of CYP4F2 and VKORC1 polymorphisms in carotid plaque formation and risk of AIS, and we showed that polymorphisms in the VKORC1 and CYP4F2 genes might increase the probability of plaque carotid formation and may increase the risk of AIS in patients without a determined embolic source [13,14]. Several of these genetic variants involved in VK metabolism may influence long-term outcomes after AIS. The VKORC1 rs9923231 (-1639 G > A) polymorphism reduces VKORC1 expression, which will lead to a reduced recycling of vitamin K and will decrease the activation of VK-dependent proteins [15]. These proteins, mainly matrix Gla protein (MGP) and growth arrest-specific gene 6 (Gas6), have a very important role in arterial integrity, inhibition of calcification, and neurovascular repair [16]. The GGCX rs11676382 polymorphism can alter the γ-carboxylation process which is required for functional activation of these proteins. This can further increase the arterial dysfunction [17]. The CYP4F2 rs2108622 (V433M) variant reduces hepatic catabolism of vitamin K1, which can decrease its systemic availability and affect the arterial homeostasis [18]. Because VK-dependent proteins maintain vascular integrity, perturbations in the VKORC1–GGCX pathway (and VK catabolism via CYP4F2) may influence stroke outcomes—even in the absence of VK antagonists.
Clinical, demographic, imaging, and biochemical data are used alone or in combination as predictors for long-term mortality of patients with AIS. Among them, advanced age, male gender, AIS severity (quantified by NIH Stroke Scale (NIHSS)), comorbidities (atrial fibrillation (AF), diabetes mellitus (DM)), and neuroimaging markers (lesion volume, white matter damage) were proved to be associated with an increased risk of death [19,20,21,22]. Despite using these multiple and diverse factors, current prognostic models lack precision and misidentify biologically vulnerable patients with apparently similar clinical/biochemical/imaging profiles.
Taking into consideration the AIS burden and the role of VK in vascular diseases, we evaluated the prognostic value of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 polymorphisms for 5-year mortality after AIS, together with established clinical and imaging predictors (age, NIHSS, lesion volume, comorbidities), in patients not treated with VK antagonists.

2. Materials and Methods

This was a prospective, longitudinal, analytical cohort study. Patients diagnosed with AIS admitted at the Department of Neurology of the Emergency County Hospital of Cluj-Napoca between March 2019 and February 2020 were enrolled in the study. The study protocol was approved by the Ethics Committee of “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania (no. 63/11 March 2019). A signed informed consent form was required before enrollment. The diagnosis of AIS was established by clinical and imaging criteria in accordance with the guidelines in place at that time [23].
The following inclusion criteria were set: patients diagnosed with new AIS confirmed by imaging techniques (head CT performed within one hour of admission to the emergency unit), who signed a written informed consent form.
Exclusion criteria were patients with hemorrhagic stroke, history of ischemic stroke, receiving vitamin K antagonists, active cancer, autoimmune diseases, liver cirrhosis, heart failure, history of acute myocardial infarction, acute coronary syndrome, and end-stage renal disease. Patients who died in the first 30 days after the AIS were also excluded.
Demographic, clinical, and laboratory data were noted for each patient: age, gender, living environment, smoking status, body mass index, presence of obesity, ischemic heart disease (IHD), arterial hypertension (AH), AF, DM, and dyslipidemia. Blood lipid profiles were also recorded. The National Institute of Health Stroke Scale (NIHSS) rating was calculated by an experienced neurologist. The presence of carotid plaques was also noted. The plaques characterized by the following were noted: protrusion of the carotid wall, thicker > 1.5 mm, or more than 50% of the intima-media thickness of the adjacent area [24]. The ischemic lesion volume was manually calculated by using the ellipsoid volume formula V = 4/3 π × (A/2) × (B/2) × (C/2), where A is the greatest diameter in the axial plane, B is the diameter at 90º to A in the axial plane, and C is the craniocaudal diameter. Measurements were performed by a radiologist and neurologist trained in neuroimaging. We selected the ellipsoid method because it provides a rapid, reproducible estimate of infarct volume on routine head CT without dedicated software. The approach is frequently used in AIS volumetry and is easy to standardize across raters.
Peripheral blood was collected in a vacutainer containing ethylenediaminetetraacetic acid. DNA extraction was performed using a genomic DNA purification kit (Wizard Genomic DNA Purification Kit; Promega, Madison, WI, USA) following the manufacturer’s instructions. Genotyping of the VKORC1 rs9923231 (-1639G > A; VKORC1*2), CYP4F2 rs2108622 (1347C > T), and GGCX rs11676382 (12970C > G) polymorphisms was performed as previously described.
Patient management was in accordance with the European guidelines at that time. Reperfusion therapy with alteplase was administered to eligible patients within 4.5 h of symptom onset after exclusion of intracranial hemorrhage on head CT. Aspirin (160–325 mg) was administered within 24 to 48 h. In patients with AF, direct oral anticoagulants were introduced. AH was treated with the appropriate drugs, taking into consideration the comorbidities. Statin therapy was prescribed unless contraindicated. Early mobilization and physiotherapy were initiated following the department protocol.
Mortality was noted if it occurred within five years following the 30 days after discharge, using the National Health Insurance House registry.
Statistical analysis was performed using MedCalc® Statistical Software version 23.1.6 (MedCalc Software Ltd., Ostend, Belgium; https://www.medcalc.org; 2025). Nominal data were expressed as frequency and percentage. Normality of the distribution for quantitative data was assessed using the Shapiro–Wilk test. Non-normally distributed data were represented as median and 25–75 percentile. Comparisons between groups were performed using Mann–Whitney or chi-square tests, whenever appropriate. ROC analysis was used to establish a cutoff value for the association of several variables with mortality. Variables that achieved a p-value of <0.05 in the univariate analysis were introduced in the multivariate logistic regression. Multivariate logistic regression was used to identify variables that were independently associated with mortality. Statistical significance was considered at p < 0.05 in univariate analysis, and p < 0.007 for multivariate analysis (Bonferroni correction).

3. Results

We recorded 71 (28.1%) deaths after 5 years after enrollment. Table 1 shows the comparisons between survivors and deceased, regarding clinical, biochemical, and imagistic variables. Deceased patients tended to be older, much more often females, with lower triglycerides, an increased prevalence of carotid plaques, a larger lesion volume, were less likely to have received thrombolysis, had a higher NIHSS score, and were more likely to harbor the VKORC1 homozygous genotype. Baseline comparisons in Table 1 are unadjusted and therefore descriptive. The p-values from this univariate analysis should not be interpreted as independent effects.
ROC analysis showed the cutoff values for mortality (Table 2). For age, a cutoff value of 72 years was calculated for 5-year mortality. For lesion volume, a cutoff of >12.63 mL was calculated for 5-year mortality. For NIHSS, a cutoff value of 7 was calculated for 5-year mortality. For TG a cutoff value of 110 mg/dl was calculated for 5-year mortality.
Multivariate logistic regression was employed to find out which variables are independently associated with mortality (Table 3). After applying the Bonferroni correction, advanced age > 72 years, volume > 12.63 mL, and a NIHSS score > 7 were the only variables independently associated with death. VKORC1 (-1639G > A) SNP m/m variant was only marginally associated with mortality. Thrombolysis was also a marginally protective factor.

4. Discussion

In this study, we investigated the predictive role of several polymorphisms implicated in the VK metabolism (VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382) for 5-year mortality in patients with AIS. The results showed that the CYP4F2 and GGCX variants are not associated with long-term mortality. The VKORC1 polymorphism was only marginally associated with a higher risk of death. Advanced age, stroke severity, and lesion volume were the most important predictive factors for 5-year mortality in patients with AIS. To our knowledge, this is the first study to observe the potential predictive role of these polymorphisms for long-term mortality in patients not following a VK antagonists’ treatment.
VK helps maintain vessel homeostasis by activating protective proteins via γ-carboxylation: VKORC1 recycles VK, GGCX performed the activation step, and CYP4F2 influences VK breakdown. When this complex system does not function adequately, proteins like MGP and Gas6 will function improperly, which may favor vascular calcification and endothelial dysfunction and therefore could affect stroke recovery. The genes, whose polymorphisms were studied in our research (VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382), have specific roles in vitamin K homeostasis (hepatic and extra-hepatic), and their mutation can affect several VK-dependent proteins [25]. The VKORC1 rs9923231 variant is responsible for a reduced regeneration of vitamin K hydroquinone from vitamin K epoxide [15]. This causes a decrease in the γ-glutamyl carboxylation of VK-dependent proteins by GGCX, including MGP, Gas6, protein S, and several coagulation factors (II, VII, IX, and X) [26]. The GGCX rs11676382 polymorphism reduces the catalytic efficiency even further, which can result in biologically inactive proteins due to their undercarboxylated nature (MGP and Gas6) [17]. MGP is one of the most potent endogenous inhibitors of arterial calcification. It binds calcium ions and prevents the accumulation of hydroxyapatite crystal in the vascular media [27]. If MGP is inactivated or its activity is reduced, it can lead to an accelerated vascular smooth muscle cell transformation into a specific osteoblast-like cell, an extracellular matrix remodeling, and increased arterial stiffness [28]. These pathways are strongly associated with recurrent ischemic events and higher cardiovascular mortality [29,30,31,32]. Gas6 is a secreted, vitamin K-dependent protein which binds itself to TAM (Tyro3, Axl, and MerTK) receptors, which are important for maintaining homeostasis, particularly of the immune, nervous, and vascular systems. Through TAM receptors, Gas6 is implicated in the mediation of several anti-apoptotic, anti-inflammatory, and endothelial-protective pathways [33]. An undercarboxylated Gas6 has decreased affinity for TAM receptors and it reduces survival signaling in vascular smooth muscle cells, endothelial cells, and neurons [34,35]. These disruptions contribute to endothelial barrier dysfunction, increased leukocyte adhesion, and compromised neurovascular repair in the post-ischemic phase and have been linked to an increased risk of recurrent vascular events and long-term mortality in AIS survivors [36,37,38,39]. The CYP4F2 rs2108622 polymorphism reduces the hydroxylation of VK1, which can shift its distribution between liver and extrahepatic tissues [18]. This can impair the MGP and Gas6 activation even further. An altered VK metabolism is associated with upregulation of pro-inflammatory cytokines and oxidative stress, resulting in an accelerated atherosclerosis and increased risk of carotid plaque rupture [40,41]. During AIS, these chronic vascular changes may predispose patients to recurrent ischemic events, hemorrhagic transformation, and impaired functional recovery, all of which increase the risk of long-term mortality. In our cohort, carriers of the m/m VKORC1 genotype were associated with a higher risk of long-term mortality. However, this association did not remain statistically significant after correction for multiple testing. This might be due to the limited sample size, as well as the modest effect size of this genetic variant when we introduced into multivariate analysis the stronger predictors such as age, lesion volume, or stroke severity. In a previous study we found the VKORC1 polymorphism was only marginally associated with the risk of AIS [14]. The results of our previous study as well as this study suggest that the effect of VKORC1 polymorphisms on AIS patients’ survival is indirect, mediated through vascular calcification or impaired activation of VK–dependent proteins. Larger, multi-center studies are needed to clarify if the observed trend represents a true biological effect.
A larger lesion volume was the most powerful predictor for long-term mortality in our study. Larger infarction areas are strongly associated with acute neurological deterioration, but also with a higher degree of neurological deficit, which may predispose AIS patients to several severe complications such as hemorrhagic transformation, extensive cerebral edema, and various infections [42,43]. The results complete our previous studies performed on different cohorts regarding the predictor role of lesion volume for in-hospital mortality of AIS patients and are in accordance with the literature findings regarding long-term mortality [44,45,46,47,48].
Advanced age is associated with severe AIS, larger infarction volumes, and it is accompanied by comorbidities like AH, AF, diabetes and/or chronic kidney disease. These factors highly reduce the survivability after an AIS. There are several arterial dysfunctions that are age-related and that might increase the recurrence of stroke and poor recovery: increased arterial stiffness and endothelial dysfunction [37,49]. Elderly patients have a decreased capacity for neuroplasticity and functional compensation after an AIS, which can contribute to disability and increased mortality rate [50]. The results of our study showed that advanced age was the second most important predictor for long-term mortality of patients after an AIS, and are consistent with several other studies [19,46,51].
The NIHSS score is a well-established and powerful predictor of long-term mortality in AIS patients, as it quantifies the stroke severity. A higher NIHSS score was independently associated with an increased 5-year mortality in AIS patients in our study. A high NIHSS score reflects greater neurological damage and is also a significant predictor for severe complications, like hemorrhagic transformation, cerebral edema, or infections, which increase the risk of short- and long-term mortality [19,44,52,53].
In our study, lower triglyceride levels were associated with higher mortality in univariate analyses, but not in multivariate regression. Even though high levels of triglycerides are considered a risk factor for stroke, there are several studies that show that low levels of triglycerides are linked to worse NIHSS, stroke complication, and increased mortality rate (the triglyceride paradox) [54,55,56]. Low triglycerides in AIS can be encountered in older patients, with a degree of sarcopenia, frailty and low energy reserves [57]. Those patients are more likely to develop infections, have poor wound healing, and, also, reduced potential for rehabilitation after AIS [58].
Gender was associated with mortality in our study only in univariate analysis. Women had a greater risk of 5 years mortality in our cohort. A meta-analysis showed that short and long-term mortality rates are significantly higher in women [59]. This likely due to older age at AIS, worse pre-stroke functional status, more severe index events, higher atrial fibrillation prevalence, and a higher prevalence of post-stroke depression [60].
BMI was lower in patients that died than in survivors, but the differences was only close to statistical significance. It likely reflects the frailty, sarcopenia, and low energy reserves. This data is consistent with studies that showed that lower BMI is associated with worse post-stroke disability and higher mortality [61].
The study has several strengths. It is, to our knowledge, the first study to evaluate the potential predictive role of VKORC1, CYP4F2, and GGCX polymorphisms for 5-year mortality in AIS patients who were not treated with VK antagonists. The patients were followed for a relatively long period, and the analysis included genetic, clinical, demographic, and imaging variables. Several limitations must be acknowledged. The sample size was relatively modest due to the extensive exclusion criteria. The single-center design may reduce the generalizability of our findings to other populations with different genetic or environmental backgrounds. At that time, few patients benefited from thrombolysis, but although the procedure is applied more frequently at present, there are still many cases that do not benefit from the procedure. Another limitation is the absence of systematically collected pre-stroke modified Rankin Scale. Larger multicenter studies are needed to validate our results.
Our results could have several practical implications. Common clinical and imaging data, such as age, NIHSS, and lesion volume, should be considered in any predictor tools for stratifying the risk of 5-year mortality. Genetic markers, like polymorphisms involved in VK metabolism, should not be determined routinely. Their practical value, especially VKORC1, will be determined in larger, multicenter studies. Future work should investigate the prognostic value of biochemical markers that quantify disturbances in VK metabolism (e.g., MGP, PIVKA-II).

5. Conclusions

In this study, we included AIS patients and showed that VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 did not independently predict mortality. The VKORC1 variant was only marginally associated with mortality, but this was attenuated after correction for multiple testing. Advanced age, NIHSS score, and the lesion volume were independent predictors of long-term mortality of AIS patients. These results suggest that these polymorphisms implicated in VK metabolism, although biologically plausible, add limited prognostic value in addition to the established clinical and imaging variables. Larger multicenter studies are needed to validate the results.

Author Contributions

Conceptualization, S.I., Ş.C.V., and A.D.B.; methodology, S.I., V.D., and A.D.B.; validation, A.E.M. and R.M.P.; formal analysis, Ş.C.V.; investigation, S.I., V.D., V.V., I.C.B., D.Ş.-L., R.M.P., L.P.-D., and O.S.C.; data curation, Ş.C.V., V.D., and C.A.C.; writing—original draft preparation, S.I. and V.D.; writing—review and editing, S.I., A.E.M., and C.A.C.; supervision, A.D.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the Declaration of Helsinki and was approved by the Ethics Committee of the “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania (no. 63/11 March 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The datasets presented in this article are available upon reasonable request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Tsao, C.W.; Aday, A.W.; Almarzooq, Z.I.; Anderson, C.A.; Arora, P.; Avery, C.L.; Baker-Smith, C.M.; Beaton, A.Z.; Boehme, A.K.; Buxton, A.E.; et al. Heart Disease and Stroke Statistics-2023 Update: A Report from the American Heart Association. Circulation 2023, 147, e93–e621. [Google Scholar] [CrossRef]
  2. 2024 Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/American Stroke Association|Stroke. Available online: https://www.ahajournals.org/doi/10.1161/STR.0000000000000475 (accessed on 9 June 2025).
  3. Nogueira, R.G.; Jadhav, A.P.; Haussen, D.C.; Bonafe, A.; Budzik, R.F.; Bhuva, P.; Yavagal, D.R.; Ribo, M.; Cognard, C.; Hanel, R.A.; et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N. Engl. J. Med. 2018, 378, 11–21. [Google Scholar] [CrossRef]
  4. Bloj, F.A.; Buicu, F.C.; Filep, C.R.; Suciu, B.A.; Vunvulea, V.; Mărginean, L. A Cost Effectiveness Analysis of Stroke Management in Romania. Gazz. Medica Ital. Arch. Sci. Mediche 2022, 181, 524–530. [Google Scholar] [CrossRef]
  5. Ioacara, S.; Tiu, C.; Panea, C.; Nicolae, H.; Sava, E.; Martin, S.; Fica, S. Stroke Mortality Rates and Trends in Romania, 1994–2017. J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. 2019, 28, 104431. [Google Scholar] [CrossRef] [PubMed]
  6. Biswas, D.M.; Murad, M.A.; Ershadian, M.; Kali, M.S.K.; Shin Sim, M.; Ibrahim, B.; Sukasem, C. Prevalence of Risk Phenotypes Associated with CYP2C9*2, *3 and VKORC1 c.-1639G>A Genetic Polymorphisms in the World Populations: Implications in Clinical Practice. Front. Pharmacol. 2025, 16, 1597379. [Google Scholar] [CrossRef]
  7. Buzoianu, A.D.; Trifa, A.P.; Mureşanu, D.F.; Crişan, S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A Polymorphisms in a Population from South-Eastern Europe. J. Cell. Mol. Med. 2012, 16, 2919–2924. [Google Scholar] [CrossRef]
  8. Limdi, N.A.; Beasley, T.M.; Crowley, M.R.; Goldstein, J.A.; Rieder, M.J.; Flockhart, D.A.; Arnett, D.K.; Acton, R.T.; Liu, N. VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose among African-Americans and European-Americans. Pharmacogenomics 2008, 9, 1445–1458. [Google Scholar] [CrossRef]
  9. Matišić, V.; Brlek, P.; Bulić, L.; Molnar, V.; Dasović, M.; Primorac, D. Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency. Int. J. Mol. Sci. 2023, 24, 13498. [Google Scholar] [CrossRef]
  10. Shendre, A.; Brown, T.M.; Liu, N.; Hill, C.E.; Beasley, T.M.; Nickerson, D.A.; Limdi, N.A. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy 2016, 36, 263–272. [Google Scholar] [CrossRef]
  11. Sipeky, C.; Weber, A.; Melegh, B.I.; Matyas, P.; Janicsek, I.; Szalai, R.; Szabo, I.; Varnai, R.; Tarlos, G.; Ganczer, A.; et al. Interethnic Variability of CYP4F2 (V433M) in Admixed Population of Roma and Hungarians. Environ. Toxicol. Pharmacol. 2015, 40, 280–283. [Google Scholar] [CrossRef]
  12. King, C.R.; Deych, E.; Milligan, P.; Eby, C.; Lenzini, P.; Grice, G.; Porche-Sorbet, R.M.; Ridker, P.M.; Gage, B.F. Gamma-Glutamyl Carboxylase and Its Influence on Warfarin Dose. Thromb. Haemost. 2010, 104, 750–754. [Google Scholar] [CrossRef]
  13. Vesa, S.C.; Vlaicu, S.I.; Vacaras, V.; Crisan, S.; Sabin, O.; Pasca, S.; Trifa, A.P.; Rusz-Fogarasi, T.; Sava, M.; Buzoianu, A.D. CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation. Genes 2020, 11, 822. [Google Scholar] [CrossRef] [PubMed]
  14. Iluţ, S.; Vesa, Ş.C.; Văcăraş, V.; Şipoş-Lascu, D.; Bârsan, C.; Pop, R.M.; Crişan, S.; Macarie, A.E.; Coadă, C.A.; Perju-Dumbravă, L.; et al. Association among VKORC1 Rs9923231, CYP4F2 Rs2108622, GGCX Rs11676382 Polymorphisms and Acute Ischemic Stroke. Medicine 2023, 102, e34836. [Google Scholar] [CrossRef]
  15. Rieder, M.J.; Reiner, A.P.; Gage, B.F.; Nickerson, D.A.; Eby, C.S.; McLeod, H.L.; Blough, D.K.; Thummel, K.E.; Veenstra, D.L.; Rettie, A.E. Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N. Engl. J. Med. 2005, 352, 2285–2293. [Google Scholar] [CrossRef]
  16. Barrett, H.; O’Keeffe, M.; Kavanagh, E.; Walsh, M.; O’Connor, E.M. Is Matrix Gla Protein Associated with Vascular Calcification? A Systematic Review. Nutrients 2018, 10, 415. [Google Scholar] [CrossRef]
  17. Hao, Z.; Jin, D.-Y.; Chen, X.; Schurgers, L.J.; Stafford, D.W.; Tie, J.-K. γ-Glutamyl Carboxylase Mutations Differentially Affect the Biological Function of Vitamin K–Dependent Proteins. Blood 2021, 137, 533–543. [Google Scholar] [CrossRef] [PubMed]
  18. McDonald, M.G.; Rieder, M.J.; Nakano, M.; Hsia, C.K.; Rettie, A.E. CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant. Mol. Pharmacol. 2009, 75, 1337–1346. [Google Scholar] [CrossRef] [PubMed]
  19. Bârsan, I.C.; Iluţ, S.; Tohănean, N.; Pop, R.M.; Vesa, Ş.C.; Perju-Dumbravă, L. Development and Validation of a Predictive Score for Three-Year Mortality in Acute Ischemic Stroke Patients. Medicina 2024, 60, 1413. [Google Scholar] [CrossRef] [PubMed]
  20. Ren, H.; Wang, D.; Wang, X.; Wu, J.; Huang, J.; Jin, H.; Huang, C.; Lei, L. Association between Periventricular Hyperintensity or Deep White Matter Hyperintensity and Outcomes of Patients with Ischemic Stroke. Front. Neurol. 2025, 16, 1583318. [Google Scholar] [CrossRef]
  21. Szlachetka, W.A.; Pana, T.A.; Tiamkao, S.; Clark, A.B.; Kongbunkiat, K.; Sawanyawisuth, K.; Bettencourt-Silva, J.H.; Kasemap, N.; Mamas, M.A.; Myint, P.K. Impact of Diabetes on Complications, Long Term Mortality and Recurrence in 608,890 Hospitalised Patients with Stroke. Glob. Heart 2020, 15, 2. [Google Scholar] [CrossRef]
  22. Elsheikh, S.; Hill, A.; Irving, G.; Lip, G.Y.H.; Abdul-Rahim, A.H. Atrial Fibrillation and Stroke: State-of-the-Art and Future Directions. Curr. Probl. Cardiol. 2024, 49, 102181. [Google Scholar] [CrossRef]
  23. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2018, 49, e46–e99. [Google Scholar] [CrossRef]
  24. Casadei, A.; Floreani, M.; Catalini, R.; Serra, C.; Assanti, A.P.; Conci, P. Sonographic Characteristics of Carotid Artery Plaques: Implications for Follow-up Planning? J. Ultrasound 2012, 15, 151–157. [Google Scholar] [CrossRef] [PubMed]
  25. Tie, J.-K.; Stafford, D.W. Structural and Functional Insights into Enzymes of the Vitamin K Cycle. J. Thromb. Haemost. JTH 2016, 14, 236–247. [Google Scholar] [CrossRef]
  26. Shearer, M.J.; Newman, P. Recent Trends in the Metabolism and Cell Biology of Vitamin K with Special Reference to Vitamin K Cycling and MK-4 Biosynthesis. J. Lipid Res. 2014, 55, 345–362. [Google Scholar] [CrossRef]
  27. Bäck, M.; Aranyi, T.; Cancela, M.L.; Carracedo, M.; Conceição, N.; Leftheriotis, G.; Macrae, V.; Martin, L.; Nitschke, Y.; Pasch, A.; et al. Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement from the COST Action EuroSoftCalcNet. Front. Cardiovasc. Med. 2019, 5, 196. [Google Scholar] [CrossRef]
  28. Durham, A.L.; Speer, M.Y.; Scatena, M.; Giachelli, C.M.; Shanahan, C.M. Role of Smooth Muscle Cells in Vascular Calcification: Implications in Atherosclerosis and Arterial Stiffness. Cardiovasc. Res. 2018, 114, 590–600. [Google Scholar] [CrossRef]
  29. Jaminon, A.; Reesink, K.; Kroon, A.; Schurgers, L. The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification-Related Processes. Int. J. Mol. Sci. 2019, 20, 5694. [Google Scholar] [CrossRef] [PubMed]
  30. Yu, Y.; Cai, Y.; Yang, F.; Yang, Y.; Cui, Z.; Shi, D.; Bai, R. Vascular Smooth Muscle Cell Phenotypic Switching in Atherosclerosis. Heliyon 2024, 10, e37727. [Google Scholar] [CrossRef] [PubMed]
  31. Vasan, R.S.; Pan, S.; Xanthakis, V.; Beiser, A.; Larson, M.G.; Seshadri, S.; Mitchell, G.F. Arterial Stiffness and Long-Term Risk of Health Outcomes: The Framingham Heart Study. Hypertension 2022, 79, 1045–1056. [Google Scholar] [CrossRef]
  32. Eilertsen, R.K.; Midtbø, H.; Sindre, R.B.; Waje-Andreassen, U.; Gerdts, E. Factors Associated with Progression of Arterial Stiffness in Ischemic Stroke Survivors: The Norwegian Stroke in the Young Study. Blood Press. 2024, 33, 2298308. [Google Scholar] [CrossRef]
  33. Laurance, S.; Lemarié, C.A.; Blostein, M.D. Growth Arrest-Specific Gene 6 (Gas6) and Vascular Hemostasis12. Adv. Nutr. 2012, 3, 196–203. [Google Scholar] [CrossRef]
  34. Laurance, S.; Bertin, F.-R.; Ebrahimian, T.; Kassim, Y.; Rys, R.N.; Lehoux, S.; Lemarié, C.A.; Blostein, M.D. Gas6 Promotes Inflammatory (CCR2hiCX3CR1lo) Monocyte Recruitment in Venous Thrombosis. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 1315–1322. [Google Scholar] [CrossRef]
  35. Burstyn-Cohen, T.; Hochberg, A. TAM Signaling in the Nervous System. Brain Plast. 2021, 7, 33–46. [Google Scholar] [CrossRef] [PubMed]
  36. Law, L.A.; Graham, D.K.; Di Paola, J.; Branchford, B.R. GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis. Front. Med. 2018, 5, 137. [Google Scholar] [CrossRef] [PubMed]
  37. Kleeberg, A.; Luft, T.; Golkowski, D.; Purrucker, J.C. Endothelial Dysfunction in Acute Ischemic Stroke: A Review. J. Neurol. 2025, 272, 143. [Google Scholar] [CrossRef] [PubMed]
  38. Mathias, K.; Machado, R.S.; Stork, S.; Dos Santos, D.; Joaquim, L.; Generoso, J.; Danielski, L.G.; Barichello, T.; Prophiro, J.S.; Petronilho, F. Blood-Brain Barrier Permeability in the Ischemic Stroke: An Update. Microvasc. Res. 2024, 151, 104621. [Google Scholar] [CrossRef]
  39. Callegari, K.; Dash, S.; Uchida, H.; Shingai, Y.; Liu, C.; Khodarkovskaya, A.; Lee, Y.; Ito, A.; Lopez, A.; Zhang, T.; et al. Molecular Profiling of the Stroke-Induced Alterations in the Cerebral Microvasculature Reveals Promising Therapeutic Candidates. Proc. Natl. Acad. Sci. USA 2023, 120, e2205786120. [Google Scholar] [CrossRef]
  40. Xie, Y.; Li, S.; Wu, D.; Wang, Y.; Chen, J.; Duan, L.; Li, S.; Li, Y. Vitamin K: Infection, Inflammation, and Auto-Immunity. J. Inflamm. Res. 2024, 17, 1147–1160. [Google Scholar] [CrossRef]
  41. Kaźmierczak-Barańska, J.; Karwowski, B.T. The Protective Role of Vitamin K in Aging and Age-Related Diseases. Nutrients 2024, 16, 4341. [Google Scholar] [CrossRef]
  42. Zhang, K.; Luan, J.; Li, C.; Chen, M. Nomogram to Predict Hemorrhagic Transformation for Acute Ischemic Stroke in Western China: A Retrospective Analysis. BMC Neurol. 2022, 22, 156. [Google Scholar] [CrossRef]
  43. Pohlmann, J.E.; Kim, I.S.Y.; Brush, B.; Sambhu, K.M.; Conti, L.; Saglam, H.; Milos, K.; Yu, L.; Cronin, M.F.M.; Balogun, O.; et al. Association of Large Core Middle Cerebral Artery Stroke and Hemorrhagic Transformation with Hospitalization Outcomes. Sci. Rep. 2024, 14, 10008. [Google Scholar] [CrossRef]
  44. Iluţ, S.; Vesa, Ş.C.; Văcăraș, V.; Mureșanu, D.-F. Predictors of Short-Term Mortality in Patients with Ischemic Stroke. Med. Kaunas Lith. 2023, 59, 1142. [Google Scholar] [CrossRef] [PubMed]
  45. Bârsan, I.C.; Iluţ, S.; Tohănean, N.; Pop, R.; Vesa, Ş.C.; Perju-Dumbravă, L. Resistin and In-Hospital Mortality in Patients with Acute Ischemic Stroke: A Prospective Study. J. Clin. Med. 2024, 13, 4889. [Google Scholar] [CrossRef] [PubMed]
  46. Szlachetka, W.A.; Pana, T.A.; Mamas, M.A.; Bettencourt-Silva, J.H.; Metcalf, A.K.; Potter, J.F.; McLernon, D.J.; Myint, P.K. Predicting 10-Year Stroke Mortality: Development and Validation of a Nomogram. Acta Neurol. Belg. 2022, 122, 685–693. [Google Scholar] [CrossRef]
  47. Karamchandani, R.R.; Rhoten, J.B.; Strong, D.; Chang, B.; Asimos, A.W. Mortality after Large Artery Occlusion Acute Ischemic Stroke. Sci. Rep. 2021, 11, 10033. [Google Scholar] [CrossRef]
  48. Rostami, A.; Elyassirad, D.; Vatanparast, M.; Abouei Mehrizi, M.A.; Hasanpour, M.; Rezaee, H.; Haghir, A.; Keykhosravi, E. Functional Outcome and Mortality Predictors in Patients with Cerebral Ischemic Infarction After Decompressive Craniectomy: Cross-Sectional Study. World Neurosurg. 2024, 182, e847–e853. [Google Scholar] [CrossRef]
  49. Liu, L.; Zhao, B.; Yu, Y.; Gao, W.; Liu, W.; Chen, L.; Xia, Z.; Cao, Q. Vascular Aging in Ischemic Stroke. J. Am. Heart Assoc. 2024, 13, e033341. [Google Scholar] [CrossRef] [PubMed]
  50. Aderinto, N.; Olatunji, G.; Abdulbasit, M.O.; Edun, M.; Aboderin, G.; Egbunu, E. Exploring the Efficacy of Virtual Reality-Based Rehabilitation in Stroke: A Narrative Review of Current Evidence. Ann. Med. 2023, 55, 2285907. [Google Scholar] [CrossRef]
  51. Rønning, O.M. Very Long-Term Mortality after Ischemic Stroke: Predictors of Cardiovascular Death. Acta Neurol. Scand. Suppl. 2013, 127, 69–72. [Google Scholar] [CrossRef]
  52. Kurmann, C.C.; Beyeler, M.; Grunder, L.; Lang, M.F.; Piechowiak, E.I.; Meinel, T.R.; Jung, S.; Hoffmann, A.; Seiffge, D.J.; Heldner, M.R.; et al. Association of the 24-Hour National Institutes of Health Stroke Scale After Mechanical Thrombectomy with Early and Long-Term Survival. Stroke Vasc. Interv. Neurol. 2022, 2, e000244. [Google Scholar] [CrossRef]
  53. Bryndziar, T.; Matyskova, D.; Sedova, P.; Belaskova, S.; Zvolsky, M.; Bednarik, J.; Brown, R.D.; Mikulik, R. Predictors of Short- and Long-Term Mortality in Ischemic Stroke: A Community-Based Study in Brno, Czech Republic. Cerebrovasc. Dis. Basel Switz. 2022, 51, 296–303. [Google Scholar] [CrossRef]
  54. Yuan, X.; Huang, S.; Ni, J.; Dong, W. Association between Blood Triglycerides and Stroke-Associated Pneumonia: A Prospective Cohort Study. BMC Neurol. 2025, 25, 83. [Google Scholar] [CrossRef]
  55. Jain, M.; Jain, A.; Yerragondu, N.; Brown, R.D.; Rabinstein, A.; Jahromi, B.S.; Vaidyanathan, L.; Blyth, B.; Stead, L.G. The Triglyceride Paradox in Stroke Survivors: A Prospective Study. Neurosci. J. 2013, 2013, 870608. [Google Scholar] [CrossRef]
  56. Cheng, K.-H.; Lin, J.-R.; Anderson, C.S.; Lai, W.-T.; Lee, T.-H. Lipid Paradox in Statin-Naïve Acute Ischemic Stroke but Not Hemorrhagic Stroke. Front. Neurol. 2018, 9, 541. [Google Scholar] [CrossRef] [PubMed]
  57. Jiang, Y.; Xu, B.; Zhang, K.; Zhu, W.; Lian, X.; Xu, Y.; Chen, Z.; Liu, L.; Guo, Z. The Association of Lipid Metabolism and Sarcopenia among Older Patients: A Cross-Sectional Study. Sci. Rep. 2023, 13, 17538. [Google Scholar] [CrossRef] [PubMed]
  58. Kim, S.-Y.; Cho, W.-S.; Park, C.-B.; Kim, B.-G. Effect of Sarcopenia on Functional Recovery in Acute Stroke Patients Admitted for Standard Rehabilitation Program. Medicina 2024, 60, 1716. [Google Scholar] [CrossRef] [PubMed]
  59. Guo, X.; Xiong, Y.; Huang, X.; Pan, Z.; Kang, X.; Chen, C.; Zhou, J.; Zheng, H.; Chen, Y.; Hu, W.; et al. Sex-Based Differences in Long-Term Outcomes after Stroke: A Meta-Analysis. PLoS ONE 2023, 18, e0283204. [Google Scholar] [CrossRef]
  60. Yoon, C.W.; Bushnell, C.D. Stroke in Women: A Review Focused on Epidemiology, Risk Factors, and Outcomes. J. Stroke 2023, 25, 2–15. [Google Scholar] [CrossRef]
  61. Miwa, K.; Nakai, M.; Yoshimura, S.; Sasahara, Y.; Wada, S.; Koge, J.; Ishigami, A.; Yagita, Y.; Kamiyama, K.; Miyamoto, Y.; et al. Clinical Impact of Body Mass Index on Outcomes of Ischemic and Hemorrhagic Strokes. Int. J. Stroke 2024, 19, 907–915. [Google Scholar] [CrossRef]
Table 1. Comparison of survivors and deceased patients.
Table 1. Comparison of survivors and deceased patients.
VariablesSurvivor Group (N = 181)Deceased Group (N = 71)p-Value
Age (median, IQR)70 (61; 79)78 (73; 85)<0.001
Gender
(N, %)		Male81 (44.8)12 (16.9)<0.001
Female100 (55.2)59 (83.1)
Environment
(N, %)		Urban114 (63)42 (59.2)0.6
Rural67 (37)29 (40.8)
Smoking (N, %)51 (28.2)13 (18.3)0.1
Obesity (N, %)40 (22.1)13 (18.3)0.6
BMI (median, IQR)26.9 (24.3; 29.4)25.8 (23.8; 29)0.08
AH (N, %)152 (84)61 (85.9)0.8
AF (N,%)26 (14.4)16 (23.2)0.1
IHD (N, %)25 (13.8)7 (9.9)0.5
DM (N, %)40 (22.1)17 (23.9)0.8
Dyslipidemia (N, %)164 (90.6)68 (95.8)0.1
TC (mg/dL) (median, IQR)183 (155; 207)168 (132; 210)0.1
HDL-C (mg/dL) (median, IQR)44 (38; 54)45 (37; 54)0.7
LDL-C (mg/dL) (median, IQR)105 (80.7; 129.6)101.6 (74.6; 131.6)0.7
TG (mg/dL) (median, IQR)123 (93.5; 170)95 (73; 123)<0.001
Carotid plaque (N, %)100 (55.2)56 (78.9)0.001
Lesion volume (mL)10.5 (5.8; 25.44)18.8 (10.8; 34.2)<0.001
Thrombolysis (N, %)32 (17.7)5 (7)0.03
NIHSS5 (3; 7.5)8 (5; 14.2)<0.001
CYP4F2 (1347C > T) SNP
(N, %)		w/w80 (44.2)30 (42.3)0.9
w/m80 (44.2)33 (46.5)
m/m21 (11.6)8 (11.3)
GGCX (12970C > G) SNP
(N, %)		w/w162 (89.5)62 (87.3)0.7
w/m19 (10.5)9 (12.7)
VKORC1 (-1639G > A) SNP
(N, %)		w/w53 (29.3)12 (16.9)0.01
w/m105 (58)40 (56.3)
m/m23 (12.7)19 (26.8)
VKORC1 (-1639G > A) SNP
(N, %)		w/w or w/m158 (87.3)52 (73.2)0.01
m/m23 (12.7)19 (26.8)
N: number; IQR: interquartile range; BMI: body mass index; AH: arterial hypertension; AF: atrial fibrillation; IHD: ischemic heart disease; DM: diabetes mellitus; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; w: wild-type; m: mutated; SNP: single nucleotide polymorphism.
Table 2. ROC analysis of predictors of mortality.
Table 2. ROC analysis of predictors of mortality.
VariableCutoffAUC (95CI)SeSpp
Age>72 years0.706 (0.645–0.761)78.8 (67.6–87.7)57.4 (49.9–64.8)<0.001
Lesion volume>12.63 mL0.646 (0.583–0.705)67.6 (55.5–78.2)61.8 (54.4–69.0)<0.001
NIHSS>70.702 (0.641–0.757)54.2 (41.9–66.3)75.1 (68.2–81.3)<0.001
TG<110 mg/dL0.676 (0.615–0.734)69 (56.9–79.5)60.7 (53.3–67.9)<0.001
AUC—area under the curve, Se—sensitivity, Sp—specificity, TG: triglycerides.
Table 3. Multivariate logistic regression for mortality.
Table 3. Multivariate logistic regression for mortality.
VariableBpOR95% C.I. for OR
MinMax
Age > 72 years1.040.0072.831.326.08
Gender (male)−0.760.080.460.191.10
Lesion volume > 12.63 mL1.40<0.0014.052.057.99
VKORC1 (-1639G > A) SNP m/m0.880.032.411.045.59
NIHSS score > 70.970.0062.641.315.31
Carotid plaque0.470.261.610.693.72
Thrombolysis−1.210.040.290.090.95
TG < 110 (mg/dL)0.630.061.880.953.74
Constant−1.38<0.0010.25
B—regression coefficient (log-odds); OR—odds ratio; CI—confidence interval; TG—triglycerides.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Iluţ, S.; Donca, V.; Macarie, A.E.; Vesa, Ş.C.; Pop, R.M.; Văcăraş, V.; Şipoş-Lascu, D.; Bârsan, I.C.; Perju-Dumbravă, L.; Chiroban, O.S.; et al. Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke. Medicina 2025, 61, 1760. https://doi.org/10.3390/medicina61101760

AMA Style

Iluţ S, Donca V, Macarie AE, Vesa ŞC, Pop RM, Văcăraş V, Şipoş-Lascu D, Bârsan IC, Perju-Dumbravă L, Chiroban OS, et al. Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke. Medicina. 2025; 61(10):1760. https://doi.org/10.3390/medicina61101760

Chicago/Turabian Style

Iluţ, Silvina, Valer Donca, Antonia Eugenia Macarie, Ştefan Cristian Vesa, Raluca Maria Pop, Vitalie Văcăraş, Diana Şipoş-Lascu, Ioana Cristina Bârsan, Lăcrămioara Perju-Dumbravă, Ovidiu Sorin Chiroban, and et al. 2025. "Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke" Medicina 61, no. 10: 1760. https://doi.org/10.3390/medicina61101760

APA Style

Iluţ, S., Donca, V., Macarie, A. E., Vesa, Ş. C., Pop, R. M., Văcăraş, V., Şipoş-Lascu, D., Bârsan, I. C., Perju-Dumbravă, L., Chiroban, O. S., Coadă, C. A., & Buzoianu, A. D. (2025). Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke. Medicina, 61(10), 1760. https://doi.org/10.3390/medicina61101760

Article Metrics

Back to TopTop